
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions β written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Vaginal cancer risk factors
Introduction
Overview
Overview
The risk factors of vaginal cancer may include vaginal adenosis, cervical cancer, diethylstilbestrol, human papillomavirus infection, HIV infection, unhealthy lifestyle, and age.
Risk factors
Risk factors
Clinical data has suggested that the development of vaginal cancer is related to several factors.
- Clinical research suggest that having adenosis increases the risk of developing clear cell carcinoma. Although it is very small, many doctors feel that any woman with adenosis should have very careful screening and follow-up[1].
- Surveys show having cervical cancer increases the risk of vaginal squamous cell cancer. This is most likely because cervical and vaginal cancers have similar risk factors[2].
- Diethylstilbestrol (DES):
- Clinical data show women whose mothers took Diethylstilbestrol (DES) develop clear-cell adenocarcinoma of the vagina more often than would normally be expected. These women are called “DES daughters”[3].
- Human papillomavirus (HPV) infection:
- Certain types of HPV (type 16 and 18) have been strongly associated with vaginal cancers[4].
- HIV infection:
- Clinical studies show human immunodeficiency virus (HIV) also increases the risk of vaginal cancer[5].
- Unhealthy lifestyle:
- Epidemiological research demonstrates smoking and alcohol increase the risk of vaginal cancer[6].
- Age:
- Approximately 85 percent of the cases of vaginal cancer occur in women who are over the age of 40, and nearly 50 percent of cases occur in women age 70 or older[7].
References
References
- β Vessey MP (1989). “Epidemiological studies of the effects of diethylstilboestrol”. IARC Sci. Publ. (96): 335β48. PMIDΒ 2680951.
- β Jain G, Sabeena S, Vasudeva A, Mundkur A, Srinivas SP, Arunkumar G, Kumar P (December 2018). “A report of human papilloma virus-16 associated vaginal carcinoma after thirty-two years of successful radiation therapy for cervical cancer”. Virusdisease. 29 (4): 537β539. doi:10.1007/s13337-018-0479-8. PMIDΒ 30539058.
- β Huo D, Anderson D, Palmer JR, Herbst AL (September 2017). “Incidence rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix: Update after 40-year follow-up”. Gynecol. Oncol. 146 (3): 566β571. doi:10.1016/j.ygyno.2017.06.028. PMIDΒ 28689666.
- β Pham T, Bi X, Hoang H, Ishizaki A, Nguyen M, Nguyen CH, Nguyen HP, Pham TV, Ichimura H (November 2018). “Human Papillomavirus Genotypes and HPV16 E6/E7 Variants among Patients with Genital Cancers in Vietnam”. Jpn. J. Infect. Dis. 71 (6): 419β426. doi:10.7883/yoken.JJID.2018.206. PMIDΒ 29962490. Vancouver style error: initials (help)
- β Davies O, Rajamanoharan S, Balachandran T (November 2015). “Cervical screening in HIV-positive women in the East of England: recent CD4 as the predictive risk factor”. Int J STD AIDS. 26 (13): 945β50. doi:10.1177/0956462414563624. PMIDΒ 25505037.
- β Santoso JT, Crigger M, English E, Wan J, Likes W (June 2012). “Smoking cessation counseling in women with genital intraepithelial neoplasia”. Gynecol. Oncol. 125 (3): 716β9. doi:10.1016/j.ygyno.2012.02.018. PMIDΒ 22366589.
- β Strander B, HΓ€llgren J, SparΓ©n P (January 2014). “Effect of ageing on cervical or vaginal cancer in Swedish women previously treated for cervical intraepithelial neoplasia grade 3: population based cohort study of long term incidence and mortality”. BMJ. 348: f7361. doi:10.1136/bmj.f7361. PMCΒ 3898577. PMIDΒ 24423603.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Syed Musadiq Ali M.B.B.S.[2]
